ZLWT-37 是一种有效的、具有口服活性的CDKs抑制剂，对CDK9和CDK2的IC50分别为 0.002 μM 和 0.054 μM。ZLWT-37 诱导 HCT116 细胞凋亡 (Apoptosis)，在 G2/M 期阻滞细胞周期。

ZLWT-37 is a potent, orally active CDKs inhibitor with IC 50 values of 0.002 μM and 0.054 μM against CDK9 and CDK2, respectively. ZLWT-37 induces apoptosis and arrests the cell cycle in the G2/M phase in HCT116 cells [1].

ZLWT-37 shows antiproliferative activity with a GI 50 of 0.029 μM for HCT116 [1].

ZLWT-37 (0-20 mg/kg; p.o.; once daily for 14 consecutive days) shows potential efficacy against the growth of implanted HCT116 cells in mice without obvious toxicity [1].

C26H30ClN5O

464

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years